



an Open Access Journal by MDPI

# **Gene-Based Vaccines**

Guest Editor:

### Dr. Michael A. Barry

Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA

Deadline for manuscript submissions: closed (31 August 2022)

### Message from the Guest Editor

The COVID-19 pandemic has brought gene-based vaccines into the forefront of human medicine, whether they be mRNA vaccines or DNA-based vaccines. This issue will examine the biology, application, immunology, and practical aspects of using gene-based vaccines for many pathogens, including SARS-COV-2.









an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

# **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

### **Contact Us**

*Vaccines* Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/vaccines vaccines@mdpi.com